Chapter 13: Impulsivity, Compulsivity, and Addiction

Impulsivity refers to the tendency to initiate rapid, unplanned actions with insufficient consideration of consequences, typically associated with reward-seeking and poor decision-making, while compulsivity describes the difficulty in stopping repetitive, maladaptive behaviors that persist despite harmful outcomes, representing the consolidation of dysfunctional habitual patterns. The neurobiological basis distinguishes two critical circuits: the ventral striatal system, comprising the ventral striatum, ventromedial prefrontal cortex, and anterior cingulate cortex, governs reward evaluation and motivational drive underlying impulsive choices; the dorsal striatal system, including the dorsal striatum and orbitofrontal cortex, mediates habitual responding and behavioral automaticity underlying compulsive actions. The transition from impulsive to compulsive control involves neuroadaptive shifts where behavioral regulation progressively transfers from ventral to dorsal circuits through learning and repeated engagement. Addiction emerges from dysregulation within the mesolimbic dopamine pathway connecting the ventral tegmental area to the nucleus accumbens, wherein drugs of abuse trigger excessive dopamine release that overwhelms natural reinforcement systems. Specific substances produce addiction through distinct mechanisms: cocaine and other stimulants block dopamine reuptake to amplify reward signaling; nicotine activates nicotinic receptors, producing desensitization and upregulation that intensifies withdrawal-driven craving; alcohol potentiates gamma-aminobutyric acid inhibition while reducing glutamatergic excitation, with reinforcement partly mediated through opioid receptors; and opioids directly activate mu-opioid receptors to produce euphoria and physical dependence. Current pharmacotherapy often fails because medications targeting acute reward do not reverse established habit circuits. Emerging approaches like pharmacological extinction employ antagonists or partial agonists administered concurrently with substance exposure to decouple conditioned stimuli from their rewarding associations, thereby extinguishing compulsive responding. The chapter also addresses investigational psychoactive compounds including ketamine, psilocybin, and MDMA being explored in therapeutic contexts to facilitate psychological change. Finally, behavioral conditions including binge eating disorder and obsessive-compulsive disorder are conceptualized within the impulsivity-compulsivity framework, with treatment strategies like selective serotonin reuptake inhibitors and exposure-response prevention targeting the dorsal circuit consolidation underlying compulsive symptomatology.